Platelet Hyperreactivity: Predictive and Intrinsic Properties

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 633-645

  Bray, Paul F ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; HEPARIN; THROMBOCYTE FACTOR 4; THROMBOXANE; TROPONIN T; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ARTERY THROMBOSIS; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PLATELET HYPERREACTIVITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SHEAR STRESS; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE VOLUME; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; THROMBOSIS;

EID: 34547114009     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.002     Document Type: Review

References (47)

1. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 (1992) 242-250
2. Fitzgerald D.J., Roy L., Catella F., et al. Platelet activation in unstable coronary disease. N Engl J Med 315 (1986) 983-989
3. DeWood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303 (1980) 897-902
4. Kroll M.H., Hellums J.D., McIntire L.V., et al. Platelets and shear stress. Blood 88 (1996) 1525-1541
5. Bolhuis P.A., Sakariassen K.S., Sander H.J., et al. Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med 97 (1981) 568-576
6. Fredrickson B.J., Dong J.F., McIntire L.V., et al. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 92 (1998) 3684-3693
7. Nieswandt B., Brakebusch C., Bergmeier W., et al. Glycoprotein VI but not alpha2beta1 is essential for platelet interaction with collagen. EMBO J 20 (2001) 2120-2130
8. Savage B., Almus-Jacobs F., and Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94 (1998) 657-666
9. Ikeda H., Nakayama H., Oda T., et al. Soluble form of P-selectin in patients with acute myocardial infarction. Coron Artery Dis 5 (1994) 515-518
10. Trip M.D., Cats V.M., van Capelle F.J., et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322 (1990) 1549-1554
11. Thaulow E., Erikssen J., Sandvik L., et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84 (1991) 613-617
12. Terres W., Hamm C.W., Ruchelka A., et al. Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty. J Cardiovasc Pharmacol 19 (1992) 190-193
13. Lam J.Y., Latour J.G., Lesperance J., et al. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 73 (1994) 333-338
14. Capanni M., Prisco D., Antonucci E., et al. The pre-procedural platelet state predicts clinical recurrence after coronary angioplasty. Int J Clin Lab Res 29 (1999) 145-149
15. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
16. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
17. Terres W., Lund G.K., Hubner A., et al. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 130 (1995) 711-716
18. Ziegler S., Maca T., Alt E., et al. Monitoring of antiplatelet therapy with the PFA-100(R) in peripheral angioplasty patients. Platelets 13 (2002) 493-497
19. Sambola A., Heras M., Escolar G., et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 15 (2004) 439-446
20. Gianetti J., Parri M.S., Sbrana S., et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 118 (2006) 487-493
21. Fuchs I., Frossard M., Spiel A., et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 4 (2006) 2547-2552
22. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
23. Smyth D.W., Martin J.F., Michalis L., et al. Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 23 (1993) 361-367
24. Huczek Z., Kochman J., Filipiak K.J., et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 46 (2005) 284-290
25. Martin J.F., Bath P.M., and Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991) 1409-1411
26. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
27. Heptinstall S., Mulley G.P., Taylor P.M., et al. Platelet-release reaction in myocardial infarction. Br Med J 280 (1980) 80-81
28. Faraday N., Braunstein J.B., Heldman A.W., et al. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 15 (2004) 9-14
29. Miyamoto S., Kawano H., Kudoh T., et al. Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary intervention. Am J Cardiol 96 (2005) 71-73
30. Miyamoto S., Kawano H., Sakamoto T., et al. Formation of platelet microaggregates correlates with adverse clinical outcome in patients with coronary artery disease. Thromb Haemost 89 (2003) 681-686
31. Kabbani S.S., Watkins M.W., Ashikaga T., et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 104 (2001) 181-186
32. Kabbani S.S., Watkins M.W., Ashikaga T., et al. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 91 (2003) 876-878
33. Turker S., Guneri S., Akdeniz B., et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 97 (2006) 198-202
34. Willoughby S.R., Stewart S., Holmes A.S., et al. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol 25 (2005) 2661-2666
35. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
36. Yee D.L., Sun C.W., Bergeron A.L., et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106 (2005) 2723-2729
37. Yee D.L., Bergeron A.L., Sun C.W., et al. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4 (2006) 2043-2050
38. Johnson M., Ramey E., and Ramwell P.W. Sex and age differences in human platelet aggregation. Nature 253 (1975) 355-357
39. Faraday N., Goldschmidt-Clermont P.J., and Bray P.F. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 77 (1997) 748-754
40. Kurrelmeyer K., Becker L., Becker D., et al. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 85 (2003) 272-277
41. Leng X.H., Hong S.Y., Larrucea S., et al. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol 24 (2004) 376-381
42. A2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 19 (1999) 1142-1147
43. Williams M.S., and Bray P.F. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood) 226 (2001) 409-419
44. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost, in press.
45. Bray P.F., and Shuman M.A. Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann's thrombasthenia. Blood 75 (1990) 881-888
46. Weiss E.J., Bray P.F., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334 (1996) 1090-1094
47. Yee D.L., and Bray P.F. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Semin Thromb Hemost 30 (2004) 591-600